Qianjiang Yongan Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO Qianjiang Yongan Pharmaceutical is Rengui Hong, benoemd in Jun2021, heeft een ambtstermijn van 3.42 jaar. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde CN¥ 1.49M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 3.4 jaar.

Belangrijke informatie

Rengui Hong

Algemeen directeur

CN¥1.9m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.4yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	8.8yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Jul 01

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Feb 27

CEO

Rengui Hong (41 yo)

3.4yrs

Tenure

CN¥1,909,100

Compensatie

Mr. Rengui Hong is Managing Director and Director of Qianjiang Yongan Pharmaceutical Co. Ltd. from June 28, 2021.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Baineng Luo	Head of the Audit Department	8.2yrs	CN¥522.50k	0.062% CN¥ 1.5m
Shi Hao Dong	Deputy General Manager	18.7yrs	CN¥1.09m	0.37% CN¥ 9.0m
Xiquan Fang	Deputy General Manager	11.3yrs	CN¥1.74m	0.097% CN¥ 2.3m
Zhihua Wang	Deputy General Manager	9.4yrs	CN¥918.30k	0.097% CN¥ 2.3m
Shaobo Li	Senior Management	5.8yrs	CN¥627.70k	0.017% CN¥ 409.9k

8.8yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002365 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rengui Hong	MD & Director	3.4yrs	CN¥1.91m	0.062% CN¥ 1.5m
Yong Chen	Chairman	18.7yrs	CN¥2.95m	21.79% CN¥ 525.5m
Yuxi Wu	Chairman of the Supervisory Board	3.4yrs	CN¥166.70k	0.19% CN¥ 4.6m
Chunxiang Zhao	Independent Director	3.4yrs	CN¥80.00k	geen gegevens
Bing Zhang	Independent Director	3.4yrs	CN¥80.00k	geen gegevens
Xu Wu	Supervisor	9.4yrs	geen gegevens	geen gegevens
Zidi Chen	Non-Independent Director	less than a year	CN¥367.60k	geen gegevens
Wen Chen	Independent Director	less than a year	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002365 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Qianjiang Yongan Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.034 loss in 3Q 2023)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.14 in 2Q 2023)

Qianjiang Yongan Pharmaceutical (SZSE:002365) Is Paying Out A Dividend Of CN¥0.10

Insufficient new directors

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.097 (vs CN¥0.051 in 1Q 2023)

Full year 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.48 profit in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Investor sentiment deteriorates as stock falls 27%

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.15 profit in 3Q 2022)

New minor risk - Profit margin trend

Full year 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.38 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) completed the acquisition of 35% stake in Wuhan Low-dimensional Materials Research Institute Co., Ltd. from Li Ganghui and Wuhan Xinlian Huida Technology Investment Partnership (Limited Partnership).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.027 (vs CN¥0.017 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.31 in FY 2019)

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥8.66

New 90-day low: CN¥9.00

New 90-day low: CN¥10.03

New 90-day low: CN¥10.32

Third quarter earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥11.10

New 90-day low: CN¥11.63

Earnings released

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd